- Home
- ANAB vs SLVM Comparison
ANAB vs SLVM Comparison
Compare ANAB & SLVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANAB | SLVM |
|---|---|---|
| Founded | 2005 | 1898 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Paper |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ANAB | SLVM |
|---|---|---|
| Price | $57.29 | $36.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $71.67 | $54.00 |
| AVG Volume (30 Days) | ★ 374.8K | 237.7K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 4.15% |
| EPS Growth | ★ 91.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $234,603,000.00 | ★ $3,351,000,000.00 |
| Revenue This Year | N/A | $0.93 |
| Revenue Next Year | $52.14 | $1.54 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $17.11 | $35.53 |
| 52 Week High | $73.30 | $56.80 |
Technical Indicators
Market Signals| Indicator | ANAB | SLVM |
|---|---|---|
| Relative Strength Index (RSI) | 50.01 | 42.79 |
| Support Level | $53.46 | $36.39 |
| Resistance Level | $57.70 | $40.13 |
| Average True Range (ATR) | 2.36 | 1.12 |
| MACD | 0.18 | -0.15 |
| Stochastic Oscillator | 41.32 | 12.29 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About SLVM Sylvamo Corporation
Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills. It produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers, and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.